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MARKER CHARACTERIZATION OF ECP-INDUCED MONOCYTE-DERIVED 
DENDRITIC CELLS  
K Liu, E Robinson, R Filler, J Lewis, R Tigelaar and R Edelson, M Girardi.    
Department of Dermatology, Yale University School of Medicine, New Haven, CT 
 
Extracorporeal photopheresis (ECP) in the treatment of cutaneous T-cell lymphoma, 
GVHD and autoimmune conditions continues to spur the question of how ECP is capable 
of inducing immunogenicity and tolerance. We previously demonstrated that ECP 
treatment leads to large-scale conversion of peripheral blood monocytes into functionally 
competent leukocytes with dendritic cell phenotypes, which may play key roles in the 
immunomodulatory capabilities of ECP.  To characterize this population of cells on a 
molecular level, we assessed for differential surface expression of selected gene-products 
on monocytes after treatment with a model-ECP apparatus.  Five gene-products 
(CXCL16, SIRPa, ICAM1, TNFR1, PLAUR) showed significant increases in surface 
expression after model-ECP treatment as compared to PBMC (p <0.01 for all). To 
identify transcription factors (TFs) expressed by ECP-treated monocytes but not 
peripheral blood monocytes, rtPCR was performed. Interactions with platelets during 
ECP passage was also assessed by using model-ECP plates coated with low- and high-
density platelets. Seven TFs demonstrated increases in mRNA after passage through the 
model-ECP plate (ΔRQ range 1.35- 6.78).  Increased platelet density induced directional 
changes in expression (RQ < 0.5) for VDR, NFkB2, CDKN1A and BCL3.  In summary, 
passage through the ECP plate apparatus caused activation of novel surface molecules 
and transcription factors that define and characterize a unique subset of “physiologically-
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I conceptualized this thesis as a movie with three side-reels.  The over-riding 
theme of all four is the goal towards the improved treatment of CTCL, as approached 
from two sides: the study of photopheresis and the analysis of peripheral blood subsets in 
CTCL.  Within the latter, we attempted to harness information from two different, but 
equally important, cellular compartments: malignant T cells vs. normal immune cells 
(such as T cells and dendritic cells).  From the malignant T cell compartment, we sought 
to better understand the pathogenesis of CTCL with the goal of discovering novel 
therapeutic targets.  From the dendritic cell side, we investigated aspects of fundamental 
biology also with the goal of discovering novel immunotherapeutics.  By accessing the 
blood of patients and healthy subjects, much was learned about the impact of these 
cellular compartments on the immune system, and the potential to harness them to 
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I.  Introduction 
 
Extracorporeal photopheresis: an immunomodulatory chameleon  
 
Extracorporeal photopheresis (ECP) is an immunotherapy initially developed in the 
1980’s by Dr. Richard Edelson et al. for the treatment of cutaneous T cell lymphoma 
(CTCL).1  The usage of ECP has since expanded to include the treatment of chronic and 
acute GVHD, prophylaxis and treatment of solid-organ transplant and several 
autoimmune diseases, such as systemic sclerosis.2-4  ECP is performed via collection of 
leukocytes from a patient using a leukopheresis device, which centrifuges whole blood to 
produce a leukocyte-rich fraction.  The buffy coat is then mixed with liquid 8-MOP, a 
photosensitizing agent, and passed through a thin plastic apparatus that allows exposure 
to controlled-doses of UVA radiation.  The compound 8-MOP is biologically inert in the 
absence of UVA, and once photoactivated, remains reactive for only microseconds, 
thereby making ECP an exceptionally safe and directable form of chemotherapy.5  Due to 
its efficacy in the treatment of CTCL and its extremely favorable side-effect profile, the 
US Food and Drug Administration expeditiously approved ECP for the treatment of 
advanced CTCL in 1988.  Since its inception, the efficacy of ECP has been studied in 
numerous uncontrolled trials for the treatment of mycosis fungoides (MF), the most 
common variant of CTCL, and Sézary syndrome (SS), a form of CTCL with malignant T 
cell involvement of the peripheral blood.  With high rates of clinical skin improvement, 
total remission and a remarkably low toxicity profile,6 ECP has become the 
recommended first-line therapy for advanced CTCL, particularly in patients with 
circulating malignant T cells in the peripheral blood.2,3,7 
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Despite its efficacy and clinical applicability, the mechanism of action of ECP remains 
not well elucidated and a heated focus of on-going research.  Early hypotheses attributed 
the effects of ECP to the destruction of malignant lymphocytes after exposure to 8-MOP 
plus UVA.  While this certainly induces apoptosis of cells, it is not sufficient to explain 
the widespread effect of ECP since only 5-10% of total lymphocytes pass through the 
treatment apparatus.8  Furthermore, ECP’s remarkable immunogenic effects in treating 
malignant diseases must be also explained in the context of tolerogenic effects seen in the 
treatment of GVHD and numerous autoimmune conditions.9 
   
 
The roles of lymphocyte apoptosis, antigen-presenting cells and regulatory T cells  
 
Treatment of the peripheral blood mononuclear cells (PBMC) with 8-MOP and UVA 
leads to large scale apoptosis of lymphocytes through the Fas/FasL and Bcl-2 related 
pathways.9  This results in the activation of apoptotic proteases leading to the 
disintegration of lymphocytes and increased apoptotic fragment uptake by antigen 
presenting cells.  ECP-treated monocytes, however, appear largely resistant to apoptosis; 
they are driven to take on more immature dendritic cell-like phenotypes as well as release 
cytokines such as IL-10 and TNF-α.10-12  Current evidence points to antigen-presenting 
cells (APC) as playing a major role in the induction of tolerance, as ECP-treated APCs, 
such as dendritic cells (DC), phagocytose apoptotic lymphoid fragments and present the 
antigen to T cells without costimulation from a true “danger” signal.  Studies have shown 
that the maturation state of DCs as well as the cytokine milieu greatly influences the 
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generation of the local immune response.  The presence or lack of an inflammatory 
environment and the presence of mature vs. immature dendritic cells can skew the 
development towards an immunostimulatory or immunosuppressive state.13  Surveillance 
of the immune system by regulatory T cells (Treg) is not studied in this thesis but deserve 
mention as another key player in ECP-induced immune modulation.  The population of 
CD4+CD25+ regulatory T cells is increased after ECP along with high expression levels 
of CD45RO and Foxp3, a finding suggestive of how ECP might dampen autoimmune 
responses and induce immune tolerance.14,15 
 
 
Pathways of T cell co-stimulation 
 
The complex mechanisms of T cell co-stimulation may also serve to explain how ECP is 
able to establish central and peripheral self-tolerance for the treatment of GVHD and 
autoimmunity.13  Naïve CD4+ and CD8+ T cells require activation before acquiring 
effector functions, and this process is stringently regulated to ensure purposeful 
activation, and requires several signals.  The first signal involves the engagement of a 
major histocompatibility complexes (MHC) on APCs with T cell receptors (TCR) on T 
cells, which generates a specific signal involving the CD3 complex.16  Additional co-
stimulatory signals are generated through other cell surface molecules, and lastly, 
cytokines produced by APCs also influence T cell activation.17,18  These three signaling 
pathways work together to induce T cell activation and the accompanying gene 
transcription, which leads to clonal expansion and differentiation of antigen-specific T 
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cells.  Conversely, the lack of co-stimulatory molecules or purposeful suppression of 
these pathways leads to T cell anergy and immunosuppression.   
 
Examples of co-stimulatory pairs involved in T cell activation include CD28:CD80/86, 
CTLA-4:CD80/CD86, PD-1:PD-L1/2, CD40:CD154 and several others.  The classic axis 
of CD28:CD86 regulated T cell activation is very well characterized in the literature.  
Conversely, CTLA-4 also binds CD80/CD86, with even higher affinity, and in turn 
inhibits the T cell response by limiting interactions with CD28.  This decreases 
inflammatory cytokine secretion as well as suppresses clonal T cell expansion, and a 
CTLA4-Ig fusion protein has been developed specifically to inhibit this pathway of co-
stimulation in allograft rejection.19-21  Similar to CTLA4, PD-1 also possesses inhibitory 
activity and plays an important role in suppressing T cell activation.  The PD-1 double-
knockout mouse model has the propensity to develop autoimmunity, demonstrating the 
importance of PD-1 in the maintenance of central and peripheral tolerance.  Similarly, 
blocking antibodies against PDL1 results in increased antigen-specific T cell expansion 
and differentiation.22-24  LFA-1:ICAM interaction belongs to a family of well-
characterized integrin pathways involved in T cell migration, T cell and APC interactions 
and the provision of co-stimulatory signals.  LFA-blocking antibodies used in animal 
models have shown prolongation in the survival time of several solid organ transplants, 
demonstrating the importance of ICAM co-stimulation in T cell clonal expansion.25-27  
The activities of these co-stimulatory pathways highlight the diversity of molecules 
involved in all stages of the immune response, as well as the pivotal role of APCs in 
promoting or suppressing T cell activation/differentiation and cytokine production16.  
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Within this complex yet specific network of signaling molecules may lie the answer to 
how ECP is able to enhance or attenuate the immune response. 
 
 
Dendritic cells: key players in adaptive immunity  
 
The understanding of dendritic cell physiology has evolved tremendously since their first 
observation in the skin by Paul Langerhans.  They are known for their unparalleled 
activity as “sentinel” cells” that bridge the innate and adaptive immune systems.28  
Dendritic cells are not only capable of stimulating naïve T cells in the presence of danger 
signals, but they also interact with T cells on a continuous basis in the absence of foreign 
antigen to enforce peripheral T-cell tolerance.29,30  In humans, DCs can originate from 
lymphoid and myeloid lineages.  “Classical” DCs (cDCs) are considered to be those 
derived from myeloid committed CD34+ progenitor cells, and monocyte-derived DCs 
(mDCs) can also form in the presence of GMCSF and ILF-4 ± TNFα.  These DCs, when 
mature, are known as interstitial DCs, which can activate naïve CD4+ and CD8+ T cells 
as well as induce differentiation of naïve B cells.  DCs that originate from CD34+ cells 
committed to the lymphoid lineage, on the other hand, become plasmacytoid DCs 
(pDCs).  They are adept at cytokine secretion, especially interferon α/β, although they are 
also capable of antigen presentation in the presence of inflammation or infection.31,32  
Studies of innate or acquired DC loss provide insight into the complex roles they play in 
immunity and tolerance, since T cells receive negative, tolerizing signals from DCs but 
also require a “baseline” signaling through the TCR from DCs for survival.  This push-
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and-pull balance of interaction between T cell and DCs may fundamentally be the 
question at hand when analyzing the seemingly opposite therapeutic responses induced 
by ECP.  Take for example DC-specific deletion of αvβ8 integrin (requisite for TGFβ 
activity on T cells) or A20 (NFκB pathway negative regulator), both of which can lead to 
widespread activation of the immune system.  Alterations in gene expression either due to 
experimental manipulation, or due to therapeutic treatment, could alter the complex roles 
of DC in T cell homeostasis and immune-modulation.  The type of immune response 
elicited is likely quite nuanced, depending on the activation state and class of dendritic 
cell, their maturation status as well as the cytokine milieu in which these DC-T cell 
interactions occur.33  It is these complexities that make dendritic cell immunobiology a 
particularly worthwhile area of investigation in better understanding the efficacy of ECP, 
as it applies to both tolerance induction and anti-cancer immunization. 
 
 
Effects of ECP on monocyte to dendritic cell maturation  
 
Previous work performed by the late Dr. Berger identified an interesting phenomenon 
that occurred after the ECP processing of peripheral blood monocytes: these cells 
underwent large-scale conversion into leukocytes with dendritic cell phenotypes.34  This 
prompted a more in-depth look at these newly formed DCs, which may possess 
augmented antigen-presenting functions that enhance the anti-tumor response after ECP.  
The results demonstrated ECP’s ability to rapidly generate functionally competent DCs 
using monocytes derived from CTCL patients and healthy subjects, without the addition 
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of cytokines or multi-day culture.  Furthermore, the results support the premise that ECP 
treatment induced significant changes in gene expression, including many genes 
associated with DC differentiation and function.  The number of genes with altered 
expression after ECP treatment was substantial: 498 upregulated and 631 down-regulated 
genes were found in common between patients and normal subjects.   
 
 
Characterization of ECP-induced monocyte-derived DCs using surface molecule 
expression and transcription factor expression 
 
The study by Berger et al. made available a vast number of candidate genes amongst the 
upregulated subgroup that may serve to better define and characterize these ECP-induced 
DCs, as well as shed light on aspects of their functionality.  Our collaborator, Dr. Lieping 
Chen, also provided a list of human transmembrane genes for cross-comparison usage.   
 
DCs can also be divided into multiple subtypes with defining functions and 
characteristics.35  Furthermore, states of infection or inflammation can induce additional 
subsets of DCs from peripheral blood monocytes, which can be quite different 
functionally and molecularly.36  While the identification of various DC subsets using 
surface markers is useful, the redundancy of certain markers on other myeloid cell 
lineages and the variability of surface expression secondary to numerous internal and 
external factors can make distinguishing these subsets difficult.  Therefore, it is often 
necessary to make these distinctions using patterns of surface expression rather than a 
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single marker.  Recent studies suggest that the identification of specific DC subsets may 
require the analysis of surface phenotype, in addition to the identification of lineage-
specific transcription factors.37-39  In a study by Satpathy et al., a transcription factor (TF) 
belonging to the BTB-ZF (Broad complex, Tramtrack, Bric-à-brac, and Zinc finger) 
family, was identified as being specifically expressed in classical DCs.37  Furthermore, 
using this TF, cDCs were distinguishable from all other immune lineages.  Given the 
unique process of producing monocyte-derived DCs using ECP treatment, we wanted to 
perform in silica analysis of ECP-induced upregulated genes in search of potentially 
novel, defining transcription factors that may enable examination of further functional 
properties of these cells.  Thus, we begin this assessment of unique surface molecule 
expression and transcription factor expression with the ultimate goal of defining and 
characterizing ECP-induced monocyte-derived DCs.  This project fits nicely within a 
larger endeavor to better understand the efficacy of ECP, likely mediated in large part 
through dendritic cells, and will provide important insight into defining a process of 
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II.  Statement of Purpose 
 
 
We aimed to utilize a tabletop apparatus, the Glycotech flow chamber, as a model for the 
ECP UV-exposure plate, to assess the effect of plate-passage on peripheral blood 
monocytes.  Previous work has shown that treatment of monocytes with the ECP plate 
led to the generation of maturationally-synchronized, functionally-competent leukocytes 
with dendritic cell phenotype.  Our central hypothesis is that the passage of monocytes 
through the Glycotech chamber induces activation of specific, novel surface molecules 
that define this population of monocyte-derived dendritic cells.  We plan to accomplish 
this objective of identifying markers of global monocyte activation using flow cytometry 
to compare the differential expression of selected, surface candidate genes, with the goal 
of determining whether this differential expression alters the immuno-modulatory effects 
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III.  Methods 
 
In silica analysis of differentially expressed DC genes after ECP treatment 
Previous analysis of the ECP-induced monocyte transcriptome (performed within our 
department) revealed activation or suppression of >1000 genes common to ECP-
processed monocytes from patients and healthy subjects.  Raw data from this analysis 
was obtained, and samples separated into 1) PBMC obtained from the ECP machine pre-
treatment, and 2) post ECP treatment after overnight incubation in a platelet storage bag 
with RPMI 1640 and 15% AB serum.  Fold change in expression was calculated as ratio 
= (Average pre-ECP expression)/(Average post-ECP expression) for both health control 
and patient cohorts.  Differential gene expression was considered as >2 fold change and a 
p value of <0.05.  Only genes with net positive >2 fold change (upregulated genes) were 
chosen for further analysis, resulting in a list of 466 genes. 
 
Using a database of 1950 full-length human transmembrane genes with immunologic and 
hematopoietic cell surface expression (courtesy of Dr. Lieping Chen, Department of 
Biological and Biomedical Sciences, Yale University; full table available as supplemental 
material40), the list of 466 upregulated genes were cross-referenced to produce cell 
surface, “ECP-activated” genes shared between these two datasets.  To further select for 
genes likely to be unique to ECP-induction, five available expression profiles of human 
monocyte derived DCs grown in GMCSF and IL-4 were obtained.  Lists of upregulated 
genes between immature dendritic cells (after 3-7 days of culture) and elutriated 
monocytes were obtained from these expression profiles and individually compared to 
the list of 87 “ECP-activated” genes to produce genes unique to ECP induction. 
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An extensive literature search was performed to assess the function of these genes and 
their relationships to immunologic pathways.  Furthermore, the raw data from the original 
transcriptome analysis was recalculated to show exact numeric value of expression 
change.  Using these two strategies, genes were prioritized based on highest levels of 
differential expression after ECP treatment and/or interesting gene function to begin in 
vivo analysis in batches. 
 
Physiologic generation of human monocyte-derived DCs 
Written informed consent was obtained from all subjects in accordance with the 
Declaration of Helsinki.  The Yale Human Investigational Review Board approved the 
protocol to obtain blood from volunteers.  Aliquots of peripheral blood were procured 
and stored in 60mL heparin-treated syringes.  Mononuclear cells were isolated from the 
peripheral blood of healthy donors by Ficoll-Paque density gradient centrifugation.  The 
peripheral blood mononuclear cells (PMBC) were re-suspended in RPMI 1640 medium 
(Gibco) and separated into three experimental groups: 1) Day 0, 2) PBMC Day 1, 3) 
Plate-passed Day 1.  The “Day 0” experimental group denotes 20 x 106 cells that are 
separated and stained on the day of peripheral blood collection.  “Plate-passed Day 1” 
indicates the 80 x 106 cells that are re-suspended in 8mL RPMI 1640 and passed through 
the Glycotech plate apparatus (set-up and illustration below).  Following one-way plate 
passage, these cells are resuspended in RPMI 1640 supplemented with 15% AB serum 
and cultured for 20 hours in 6-well polystyrene tissue-culture plates at a density of 106 
cells/mL.  To generate cells for comparative phenotypic analysis (“PBMC Day 1), 60 x 
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106 cells are re-suspended in RPMI 1640, allowed to sit in the incubator to simulate 
temperature conditions for the Plate-Passed experimental group, cultured for 20 hours 
similar to conditions described above and collected for FACS analysis. 
 
Glycotech Plate Chamber 
Previous research performed by our group had demonstrated that human monocytes 
could be efficiently converted to dendritic antigen presenting cells by passage over a 
platelet-coated plastic surface.  This is in contrast to conventional methods of in vitro 
monocyte-to-DC conversion, which requires the addition of exogenous growth factors.  
Briefly, a polystyrene surface is coated with autologous platelet-rich plasma and allowed 
to form an immobilized platelet layer.  A Glycotech flow chamber is placed on top of this 
surface and vacuum-sealed, and 4ml of RPMI 1640 is passed through at 1 ml/min and 
discarded during the wash step.  PMBC (“Plate-Passed” experimental condition) is 
passed through the chamber at 0.8 ml/min to allow for ample interaction time between 
monocytes and the platelet coating.  Subsequently, 40 ml RPMI is passed through the 
chamber at 8 ml/min to create high velocity flow to remove any adherent monocytes.  
The total 48 ml collected during PBMC plate passage and high-velocity wash phases is 
combined and cultured for 20 hours and harvested for phenotyping analysis using multi-
parametric flow cytometry (Figure 1). 
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Figure 1.  Diagram of experimental setup using the Glycotech flow chamber.  
Peripheral blood monocytes are passed over a platelet-coated polystyrene surface under 
vacuum seal under specific experimental conditions: PBMC is passed through the 
chamber at 0.8 ml/min followed by flushing of the chamber with 40ml RPMI at 8 
min/ml.  All volume after passage is collected for overnight culture.  *Graphic depiction 
courtesy of David Khalil, Yale Department of Dermatology. 
 
FACS analysis 
All three experimental groups were analyzed by flow cytometry.  In all samples, cells 
were also paired with matching isotype controls.  Monoclonal antibodies specific for 
monocytes and DC maturation included: CD14 (lipopolysaccharide receptor, monocytes); 
HLA-DR (human leukocyte antigen DR; class II major histocompatibility complex 
[MHC] molecule); CD83 (DC marker); and CD80 and CD86 (B7.1 and B7.2 co-
stimulatory molecules).  Cells were blocked with 1:100 normal mouse IgG in 5% AB 
serum for 15 minutes then incubated with selected antibodies targeting prioritized surface 
molecules for 30min at 4°C (Table 1).  Anti-CATB and anti-Neu1 rabbit polyclonal 
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antibodies required wash and incubation with FITC-conjugated donkey anti-rabbit 
antibody for an additional 30 min at  4°C.  Cells were then washed three times and fixed 
in 2% paraformaldehyde.  To determine the ability of plate passage to induce DC 
maturation markers, cells were incubated with PE-conjugated anti-CD83, -CD86, FITC-
conjugated anti-HLA-DR, -CD80, PCP-conjugated anti-CD11c and APC-conjugated 
anti-CD14.  All flow cytometric data were analyzed using FlowJo software (Tree Star).  
Monocyte-derived DC populations are identified as CD11c+ cells with appropriate 
forward and side scatter. 
 
Table 1.  Selected antibodies targeting prioritized surface molecules. 
Name Manufacturer Catalog # 
CTSB (rabbit pAb) Abgent (San Diego, CA) AP7367c  
CXCL16 (anti-human APC-conj. mAb) R&D Systems (Minneapolis, MN) FAB976A  
ICAM1 (anti-human PE-conj. mAb) eBioscience (San Diego, CA) 12-0549 
MSR1 (anti-human PE-conj. mAb) R&D Systems (Minneapolis, MN) FAB2708P  
Neu1 (Rabbit pAb) Abgent (San Diego, CA) AP9697c  
OLR1 (anti-human PE-conj. mAb) R&D Systems (Minneapolis, MN) FAB1798P  
PLAUR (anti-human APC-conj. mAb) eBioscience (San Diego, CA) 17-3879 
PMP22 (anti-human DyLight 288-conj. mAb) Novus Biologicals (Littleton, CO) NB110-59086G  
SIPRα (anti-human APC-conj. mAb) eBioscience (San Diego, CA) 17-1729 
TNFRSF1A (anti-human PE-conj. mAb) R&D Systems (Minneapolis, MN) FAB225P  
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In silica identification of upregulated transcription factors after ECP induction 
Using the previously delineated list of 466 upregulated genes from the ECP-induced DC 
transcriptome, transcription factor genes were identified using the TFCat 
(http://www.tfcat.ca/index.php) database.   
 
RNA isolation and gene expression analysis 
Peripheral blood monocytes from a single donor were separated into three subsets: 
Sample A = monocytes cultured overnight following passage over plate coated with low 
density of platelets; Sample B = monocytes cultured overnight following passage over 
plate coated with high density of platelets; Sample C = monocytes cultured overnight 
without plate-passage.  Total RNA was isolated from each subset using the RNeasy 
MicroKit (Qiagen, Valencia, CA).  cDNA was then prepared from three samples of RNA 
using ABI High Capacity cDNA Reverse Transcription kit with RNase Inhibitor (ABI, 
Foster City, CA).  Amplification of cDNA was achieved using TaqMan Pre-Amp 
Mastermix and TaqMan assays specific to the eight transcription factors, all according to 
manufacturer’s protocol.  Real-Time PCR was performed using TaqMan Gene 
Expression Master Mix with TaqMan assays.  Ct values obtained were normalized 
against housekeeping gene HPRT1 and ΔCT calculated using Sample C as baseline.  The 
expression difference between conditions was calculated using RQ = 2-ΔΔCT.  Monocyte 
processing done by Tyler Durrazzo (YMS Class of 2010); RNA isolation performed by 
Renata Filler; RNA expression analysis performed by Kristina Liu under the guidance of 
Renata Filler.   
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IV.  Results 
 
In silica analysis identifies 66 upregulated transmembrane genes after ECP induction 
 
Comparison of the database of 466 upregulated genes identified via RNA array against 
the list of 1950 full-length human transmembrane genes with immunologic and 
hematopoietic cell surface expression yielded 87 genes in common.  Further comparison 
against five expression profiles of human monocyte derived DCs grown in culture with 
GMCSF and IL-4 yielded 66 genes unique to ECP induction.  Assessment of gene 
function, known relationship to immunologic pathways, and the comparison of raw 
transcriptome data prioritized 12 candidate genes for initial testing (Table 2). 
 
Table 2. ECP-enhanced expression of cell surface/transmembrane genes.  The 12 
genes tested during the first round of experiments are shown in bold.   
 
ABCA1  ENG KCTD11 OLR1 SC5DL STX6 
ACVR1B FLOT1 LAMP2 OMG SEMA6B TM9SF1 
ATP6V0B GNA15 LEPROT PI4K2A SIRPA TMBIM1 
BASP1 GPR137B MARCKSL1 PLAUR SLC1A4 TMEM33 
BEST1 GPR157 MCOLN1 PMP22 SLC22A4 TNFRSF10B 
CPM HEXB MFAP3 PVRL2 SLC31A1 TNFRSF11A 
CRK HOMER3 MGAT4B RAB13 SLC35E3 TNFRSF1A 
CSF2RA ICAM1 MR1 RAB8B SLC39A6 TNFRSF1B 
CTNND1 IRAK1 MRAS RAB9A SLC6A6 TNFSF14 
CTSB ITGA5 MSR1 RALA SLC6A8 TNFSF9 
CXCL16 ITGB8 NEU1 RNASE1 STX3 YKT6 
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Plate passage induces dendritic cell phenotype in normal subjects 
 
We confirmed findings from previous investigations that plate-passage can induce a 
dendritic cell phenotype on processed monocytes from normal subjects 34.  We analyzed 
the co-expression of CD83 (a marker of early DC maturation) and HLA-DR (highly 
expressed in DCs) to assess for evidence of a monocyte to DC transition in six normal 
subjects. The peripheral blood from these subjects was processed through the Glycotech 
chamber as a laboratory model of the ECP exposure plate.  Twelve separate analyses of 
peripheral blood samples were run (two blood draws per normal subject on separate 
dates).  
 
We observed large increases in the percentage of monocytes co-expressing CD83 and 
HLA-DR in both plate-passed and overnight cultured monocytes (Figure 1A).  While 
overnight culture alone produced an increase of 12.8% in co-expression of these two 
surface markers, plate-passage in addition to overnight culture resulted in an additional 
5.2% increase in expression.  As shown in Figure 2, the last set of bars indicate the mean 
± SD for all 11 blood draws (patient n=6), revealing significant enhancement in 
CD83/HLA-DR co-expression between plate-passed and overnight culture conditions 
(p<0.01) and the plate-passed and overnight culture versus day 0 conditions (p<0.0001 
for both comparisons).  Of note, the repeat blood draw from Subject 5 yielded very 
different results from the rest of the cohort such that it was deemed an outlier and not 
incorporated into statistical calculation.  The membrane expression of the co-stimulatory 
molecules CD80 and CD86 were increased after both overnight culture and plate-
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passage, as demonstrated by representative flow cytograms; however differences in the 
expression of these markers did not differ dramatically between overnight culture and 
plate-passage (Figure 2A).  As expected with monocyte to DC transition, surface 
expression of CD14 is decreased in both plate-passed and overnight culture conditions 
(Figure 2B).  These results confirm previous analyses performed by our laboratory 
demonstrating that monocytes can be induced to enter the DC differentiation pathway 
after both overnight culture and plate-passage.  More significantly, plate passage is able 
to induce greater expression of DC maturation markers than overnight culture alone.   
 
Figure 2.  The percentage of monocytes induced to become leukocytes with DC 
phenotype as analyzed by the percentage of cells co-expressing CD83 and HLA-DR.  
The three experimental conditions indicate: D0= fresh PBMC; Overnight culture = 
cultured overnight in media without cytokines; Plate = passage through the Glycotech 
chamber and cultured overnight without cytokines.  Dual-color flow cytometry analysis 
was performed on each experimental condition from 11 blood draws using 6 healthy 
donors.  Monocyte population was gated on CD11c+ population and confirmed using 
forward and side scatter.  Data bars to the right of graph are the mean ± SD.  *, P < 0.01, 
compared with D0; **, P < 0.01, compared with Overnight Culture.   
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Figure 3.  (A) Increase in co-expression of CD80 and CD86 on monocytes after 
overnight culture and plate-passage.  Representative flow cytograms from 3 donors 
showing markers of maturation at three experimental conditions: D0= fresh PBMC; 
Overnight culture = culture overnight in media without cytokines; Plate = passage 
through the Glycotech chamber and cultured overnight without cytokines.  Donor 1 is 
represented in the top 3 graphs, Donor 2 is represented in the middle graphs and Donor 4 
is represented in the bottom graphs.  Donors 3, 5, and 6 had similar trends of co-
stimulatory marker expression (data not shown).  Two-color membrane staining using 
CD80 (FITC) and CD86 (PE) was performed for the identification of surface expression.  
(B) Decrease in surface expression of CD14 after overnight culture and plate-
passage.  Monocytes undergoing the transition to leukocytes with DC phenotype were 
further assessed for loss of CD14+ surface expression.  The three experimental conditions 
are the same as in Figure 2.  Change in CD14+ expression calculated as the difference in 
mean fluorescent intensity (MFI) between CD14 antibody and isotype control antibody 
for each subject and condition.  Data bars to the right of the graph indicate mean ± SD.  *, 
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Induction of selected surface markers in treated monocytes 
 
Monocytes in the plate-passed condition are culture overnight for 18 hours to allow 
sufficient time for gene activation, cell maturation and surface marker expression.  To 
assess whether the observed phenotypic changes are a result of monocyte interaction with 
platelets and the plastic plate surface, we cultured a portion of each patient’s monocytes 
overnight without plate-passage to eliminate any confounding influences exerted from 
overnight culture alone.  Baseline surface expression is established by staining PBMC on 
the day of sample collection.  Expression of the 12 selected surface markers was assessed 
using flow cytometry.  The monocyte population was gated using forward and side 
scatter and confirmed by CD11c staining.  A representative flow cytometry histogram of 
one of the healthy subjects tested is shown in Figure 4 to demonstrate the use of ΔMFI 
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Figure 4.  Representative flow cytometric histogram comparing a normal subject’s 
monocyte population at Day 0, after overnight culture, and after plate-passage. 
Numbers in blue and red denote units of fluorescent intensity for isotype control (APC-
IgG1) and PLAUR antibody (APC-PLAUR).  ΔMFI = MFI of candidate antibody (red) – 
MFI of isotype control antibody (blue).  Monocyte population gated on CD11c+ 
population and confirmed using forward and side scatter.  2.67 fold and 6.55 fold 
increases in expression are seen after overnight culture and plate passage, respectively, as 
compared to fresh PBMC.  
 
 
This typical flow cytometric histogram of a normal subject’s monocyte population 
reveals marked increases in expression after overnight culture and plate passage.  This is 
mostly to demonstrate the way we calculated change in expression using ΔMFI 
(subtraction of background isotype control fluorescence from fluorescent intensity of 
antibody staining).  Here we see significant increases in ΔMFI after both overnight 
culture and plate passage, and more interestingly, an increase from overnight culture to 
plate passed.   
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Twelve selected genes were tested using the three experimental conditions stated above.  
Statistically significant changes in expression after plate-passage was identified in five 
genes: ICAM1, PLAUR, TNFR1, CXCL16 and SIRPa.  Three of these five genes, 
ICAM1, PLAUR and TNFR1, further demonstrated significant differences in expression 
between the plate-passed and overnight culture conditions.  Only one gene, TNFR1, was 
found to have down-regulation of expression after both treatment conditions (Figure 5).  
These results are consistent with previous findings of a characteristic gene expression 
profile induced by ECP treatment.  The five highly upregulated genes possess a variety of 
functions associated with DC adhesion, proliferation and function, further supporting the 
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Figure 5.  Surface markers with differential expression after plate-passage.  
Calculation of ΔMFI was performed for the twelve candidate genes across 11 separate 
trials. Five genes demonstrated significant changes in expression after plate-passage as 
compared to fresh PBMC.  Two genes showed significantly increased expression after 
plate-passage as compared to overnight culture.  Statistical analyses were performed 
using two-tailed, student’s t-test.  Significant p-values (p < 0.05) are identified in black; 
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Table 3.  Candidate genes with statistically significant increases in cell surface 
expression after plate-passage. 
 
Genes Attributes 
CXC chemokine ligand 
16 (CXCL16) 
Receptor for CXCR6 expressed on activated T cells; attracts effector and 
cytotoxic T cells 
Signal-regulatory 
protein alpha (SIRPα) 
Negative regulator of tyrosine kinase-coupled signaling pathways; 
overexpression inhibits tumor transformation and enhance tumor apoptosis 
Tumor necrosis family 
receptor 1 (TNFR1) 
Though TNF signaling, mediates immunogenic and immunomodulatory 
functions; major roles in DC maturation, T cell priming, proliferation and 
recruitment 
Intercellular adhesion 
molecule 1 (ICAM1) 




Urokinase receptor involved in degradation of extracellular matrix proteins, 
chemotaxis, and adhesion via binding to integrins; crucial in the recruitment 
of T cells 
 
 
Increased expression of 7 transcription factors distinguish ECP-treated monocyte-
derived DCs 
 
To identify transcription factors (TFs) expressed by ECP-treated monocyte-derived DCs 
but not in untreated peripheral blood monocytes, we began by performing an in silica 
analysis of the RNA array data from Berger et al.34   TFs were identified using cross-
comparison against the TFCat (http://www.tfcat.ca/index.php) database and further 
selected for DC-specific gene expression and roles in immunity through extensive 
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literature searches.  Eight candidate TFs were selected for expression comparisons by 
RT-PCR.   
 
Table 3.  TF genes with upregulated expression on RNA array. 
Genes Attributes 
B-cell leukemia/lymphoma 3  (BCL3) 
 
Expressed in bone marrow-derived DCs, substantial role in 
immune regulation; proto-oncogene candidate, identified 
in some cases of B-cell leukemia41,42 
Broad complex, Tramtrack, Bric-à-brac, 
and Zinc finger family 3  (BTBD3) 
Function largely uncharacterized; activates promoter of 
CD56, which is involved in proliferation and anti-
apoptosis43 
Broad complex, Tramtrack, Bric-à-brac, 
and Zinc finger family 4  (BTBD4) 
Selectively expressed by classical DCs (cDCs) and their 
committed progenitors37 
cAMP responsive element modulator  
(CREM) 
Possible DC maturation marker44,45; involved in multiple 
intracellular signaling cascades46  
Cyclin-dependent kinase inhibitor 1A  
(CDKN1A) 
 
Expression tightly controlled by p53, mediates G1 cell 
cycle arrest; Crucial for differentiation of peripheral blood 
monocyte precursors to functional DCs47,48  
Growth arrest and DNA-damage-
inducible 45 alpha  (GADD45A)  
Expression increases following stressful growth arrest; 
mediates activation of p38/JNK pathway; expressed in late 
maturation of DC49,50 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 2  
(NFKB2) 
One study shows NFkB2 to be requisite for DC cross-
presentation; another shows decreased NFkB2 activity 
enhances DCs’ ability to induce CD4+ T cell response51,52 
Vitamin D receptor (VDR) 
 
Nuclear hormone receptor; assists DCs in sensing their 
lipid environment and modulating the immune response53 
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To assess the effect of ECP treatment on TF expression, and to compare the impact of 
passage through a plate coated with varying densities of platelets, three sets of RNA 
samples were analyzed: Sample A= monocytes treated with a model-ECP plate coated 
with low density platelets, then cultured overnight; Sample B = monocytes treated with a 
model-ECP plate coated with high density platelets, then cultured overnight; and Sample 
C = monocytes cultured overnight without treatment.  The samples were run in triplet and 
the relative quantitation, or RQ, was calculated54.  The RQ demonstrates the fold change 
in expression of mRNA sequences in the treatment samples, Sample A and Sample B, 
relative to the same sequence in the control sample, Sample C.   
 
With the exception of GADD45A, which demonstrated essentially unchanged expression 
compared to the control (RQ = 1.02 and 1.03 for low- and high-density platelets, 
respectively), mRNA expression was increased for all seven TFs after passage through 
the model-ECP plate with high density platelets (Figure 6).  Increased platelet density 
induced directional changes in expression (ΔRQ > 0.5) for VDR, NFkB2, CDKN1A and 
BCL3.  BTBD4, a transcription factor recently identified as being specifically expressed 
in cDCs,37 demonstrated ~3 fold increases in expression after treatment (RQ = 2.89 and 
3.14 for low- and high-density platelets, respectively).  CREM, an important component 
of cAMP-mediated signal transduction and possible DC maturation marker, was 
significantly upregulated with both platelet treatments (RQ = 6.78 and 5.9 for low- and 
high-density platelets, respectively). 
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Figure 6. Seven transcription factor mRNA levels show increased expression in 
plate-passed monocyte-derived DCs vs. untreated monocytes.  Sample A (blue) 
denotes plate-passage over a low-density platelet bed; Sample B (red) denotes plate-
passage over a high-density platelet bed.  Calculation of relative quantitation (RQ) 
performed via comparison to the control condition (untreated monocytes).  Seven of the 
eight TFs demonstrated increased mRNA expression after plate-passage over high-
density platelet beds.  Increased platelet density induced directional changes in the 


























Sample A  
Sample B  
	  
	   29	  
IV.  Discussion 
 
Tremendous progress in DC research has been made in the past twenty years, starting 
with the development of a simple method for generating DCs from peripheral blood 
monocytes.55  This method of culturing monocytes for three to six days in the presence of 
GMCSF and IL-4 results in populations of immature dendritic cells, which can be further 
induced to mature with the addition of stimulatory cytokines to the media.  Results from 
studies by Berger et al. demonstrating the conversion of blood monocytes from CTCL 
patients into cells with DC phenotype raised the possibility that functional dendritic cells 
can be produced on a large scale without the addition of exogenous cytokines.34  
Conceivably, DCs produced through this method would better mimic physiologic 
signaling.  By seeking to define and characterize ECP-induced monocyte-derived DCs 
using surface markers and unique patterns of TF expression, these cells may one day be 
preferentially induced to assume immunogenic or immunosuppressive states and used to 
tailor ECP to the treatment of specific conditions.   
 
The results of this study provided evidence for a phenotypic, monocyte to DC transition 
after plate-passage, and extended results from our laboratory’s previous findings to 
validate the use of the bench-top Glycotech flow chamber as an appropriate model for the 
significantly larger ECP UV-exposure plate.  We demonstrated that plate-passage is 
critical for the induction of DC phenotype as monocytes cultured overnight produced 
significantly less differentiated leukocytes with lower surface co-expression of CD83 and 
HLA-DR, and higher surface expression of CD14.  Two of the twelve candidate genes 
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also required passage through the plate for high levels of gene activation as overnight 
culture induced comparably lower levels of expression.  Our laboratory is currently 
exploring the relationship of monocyte-to-platelet interactions as a major factor in ECP-
induced monocyte activation.  To assess whether the density of the adherent platelet bed 
alters monocyte gene activation, quantitative analysis of TF expression was performed 
using Glycotech chambers with low- and high-density platelet beds.  Four of eight TFs 
(50%) assessed demonstrated directional changes in expression with platelet density, and 
seven of eight TFs (87.5%) were found to have increased expression after plate-passage 
over the high platelet bed.  These findings further support our original hypothesis that 
plate-passage, as a model for the ECP apparatus, rapidly produces large numbers of 
monocyte-derived DCs under more physiologic environments than what previous culture 
methods allowed, and these cells possess a very distinct expression pattern that will 
enable its delineation, both in phenotype and function, from other DC subsets. 
 
The five cell surface markers that demonstrated increased expression after plate-passage 
merit further exploration for their potential roles in DC biology or DC-T cell interaction.  
These molecules, as briefly discussed in Table 2, all possess interesting DC or 
immunologically related functions.  For example, CXCL16, or CXC chemokine ligand 
16, is a transmembrane chemokine actively transcribed by myeloid DCs to attract effector 
cells with its corresponding receptor, CXCR6.56,57  It has the unique function of being 
both an endocytic receptor as well as the only known ligand of CXCR6 (CXC chemokine 
receptor 6) expressed on activated T cells.58,59  Furthermore, CXCR6 expression on 
central memory T cells becomes significantly upregulated after interaction with mature 
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DCs expressing CXCL16, suggesting that this interaction is important in supplementing 
the effector memory T cell response in states of infection and inflammation.59  CXCL16 
appears to be one of the initially produced chemokines in the setting of viral infections to 
attract effectors and cytotoxic T cells to provide a timely response to curb the infection.60  
It also acts as an inflammatory cytokine in the setting of bacterial infections via 
regulation of IFN-ɣ and cell-mediated immunity.58,61,62  In addition, membrane-bound 
CXCL16 plays important roles in antigen presentation, such as facilitating bacterial 
phagocytosis by professional APCs such as dendritic cells.62  Thus, increased CXCL16 
expression after treatment with plate-passage may indicate enhanced aptitude of these 
monocyte-derived DCs in the uptake of various pathogens and antigens as well as 
attracting T and Natural Killer T (NKT) cells.56   
 
SIRPα, or signal-regulatory protein alpha, is a transmembrane glycoprotein and negative 
regulator of receptor tyrosine kinase-coupled signaling pathways.63  It is expressed 
predominantly on monocytes, DCs and their precursors.  In 1999, Seiffert et al. identified 
the ligand for human SIRP as CD47, a broadly-expressed plasma membrane protein with 
myriad cellular functions.64  CD47 is associated with αⅴβ3 integrins and regulates integrin 
function; in the hematopoietic system, this is limited to megakaryocytes and platelets.65  
Evidence has also shown that CD47 is involved in adhesion to vitronectin, 
transendothelial migration and costimulation of T-cell activation66,67.  Ligation of SIRPα 
with a binding antibody leads to the inhibition of many leukocyte functions such as 
phagocytosis, transmigration and TNF production.68  In monocytes, SIRPα acts as a 
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negative regulator of adhesion and recruitment during inflammation, as mediated by β2 
integrins.  This is suggestive of SIRPα’s role in reducing the migration and attachment of 
monocytes and other leukocytes in the setting of inflammation.68,69  Using glioblastoma 
cells as an in vitro tumor model, overexpression of SIRPα1 led to inhibition of 
transformation and enhanced apoptosis following tumor irradiation, as well as reduced 
tumor cell migration.  These findings were thought to result from negative regulation of 
EGFR-induced PI3-K pathway activation.70  Thus it may be worth examining the 
presence of CD47 expression on CTCL cells and their interaction with plate-passed 
monocyte-derived DCs with enhanced SIRPα expression. 
 
The next upregulated candidate gene, TNFR1, is especially reflective of the multi-faceted 
nature of ECP.  TNFR1, or tumor necrosis family receptor 1, belongs to a well-known 
family of ligands and receptors that play important roles in inflammation and 
autoimmunity.  Using animal models with dysregulated TNF expression, it has been 
shown that the TNF/TNFR system possesses immunogenic and pro-inflammatory as well 
as immunomodulatory and disease-suppressive functions.71  This is supported by the 
evidence of TNF-α and its receptors’ pleiotropic roles in DC maturation, T cell priming 
and proliferation, and T cell recruitment and function.72-76  While some studies have 
shown that TNF-α is essential for T cell activation, others report that TNF-α and TNF 
receptors can actually suppress T cell immunity.  This discrepancy is thought to be a 
result of the differential timing of TNF-α release during the immune response.77-81  TNF-
α blocking agents have been used clinically with success in several inflammatory and 
autoimmune conditions without thorough understanding of the exact molecular level at 
	  
	   33	  
which TNF-α inhibitors are interfering with pathogenesis.  The results observed in our 
study showing down-regulation of TNFR1 expression after plate-passage is interesting, 
and may indicate that these newly produced monocyte-derived DCs are maintained in a 
fairly immature state, or may be reflective of a finding that is unique to the processing of 
monocytes from healthy subjects.  The combination of plate-passage without a pre-
existing antigen to initiate or sustain an immune response may decrease the relevance of 
TNF-α signaling and result in the down-regulation of its receptors.  Further analysis of 
TNFR1 expression on monocytes isolated from patients with CTCL and GVHD should 
be performed. 
 
ICAM1, or intercellular adhesion molecule 1, belongs to a class of well-studied cell 
adhesion molecules belonging to the immunoglobulin superfamily.82  ICAM1 interacts 
with its ligand LFA1 (lymphocyte function associated antigen 1), and this pairing is 
integral to many aspects of normal immune function, including immune cell migration 
and response. Members of the CAM (cellular adhesion molecule) family are responsible 
for the adhesion, rolling and migration of numerous cellular subsets, including 
monocytes, eosinophils, memory T cells and neutrophils.83  Furthermore, immunogenic 
stimuli, such as TNF-α, lead to increase cell surface expression of ICAM1, facilitating 
the recruitment of leukocytes to sites of inflammation.84  Looking specifically at ICAM1 
expression in monocytes and monocyte-derived dendritic cells (cultured in GMCSF/IL-
4), studies reflect either slight down-regulation or constant expression suggestive of 
relative non-importance in monocyte to DC differentiation.50,85  The significant increase 
in expression seen in our plate-passed monocyte-derived DCs as compared to simple 
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overnight culture suggest an element of plate-specific stimulation of these monocytes that 
may allow them to more effectively engage, for example, naïve CD8+ T cells and induce 
their activation and differentiation into potent cytotoxic T cells.86  It will be important to 
confirm published results of ICAM1 expression on classical DCs in the same 
experimental context as our plate-passed monocyte-derived DCs. 
 
PLAUR (plasminogen activator, urokinase receptor), or CD87, is an intriguing molecule 
involved in adhesion, proteolysis and chemotaxis.  When its ligand, urokinase (uPA) 
binds to PLAUR, plasminogen is converted to proteolytically active plasmin and 
facilitates extracellular matrix protein degradation.87  This enzymatic activity allows 
monocytes and dendritic cells to penetrate collagen barriers during cell-directed 
migration to the periphery or lymph nodes.88  In addition, PLAUR can bind vitronectin, 
an integrin ligand, as well as other integrins at vitronectin-independent sites.87  It also 
possesses domains with chemotactic activity; in fact, PLAUR has been found to be 
requisite for monocyte chemotaxis in in vitro experiments using blocking antibodies and 
antisense oligonucleotides.89  Studies have shown that both immature and mature 
monocyte-derived dendritic cells express low levels of PLAUR.55,90  The relevance of 
PLAUR and uPA in the generation of appropriate immune responses has been tested 
using homologous recombinant mice lacking uPA.  These animals exhibit an 
immunodeficient phenotype resulting from inadequate recruitment of T cells, and 
ultimately succumb to uncontrolled infection.89  In a study examining the role of CD87 in 
the activation of T cells by DCs, monocyte-derived DCs (after culture with GMCSF and 
IL-4) were tested in proliferation assays and mixed lymphocyte reaction assays with 
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CD87-blocking monoclonal antibodies.  These antibodies were able to inhibit autologous 
T cell proliferation as well as block the activation of naïve and memory T cells, 
highlighting the important role of PLAUR in immune induction.91  The significant 
increase in the expression of PLAUR on plate-passed monocyte-derived DCs as 
compared to DCs after overnight culture may indicate plate-passage associated 
enhancement in cell-directed migration as well as T cell stimulation.  These five cell 
surface molecules, along with other candidates in the testing pipeline, will serve to define 
and characterize this unique subset of ECP-induced monocyte-derived DCs that represent 
a more physiologic model of DCs in vivo.   
 
To complement the search for ECP-induced monocyte-derived DCs surface markers, we 
extended our in silica analysis to transcription factors.  Identification of population-
specific TFs would expand and confirm categorization based on patterns of surface 
marker expression.  Using gene expression analysis to identify TFs expressed in ECP-
induced monocyte-derived DCs, we identified seven TFs with increased expression in 
monocytes after plate-passage (over platelet beds with high and low density).  Using gene 
expression analysis to identify TFs expressed in ECP-induced monocyte-derived DCs, we 
identified seven TFs with increased expression in monocytes after plate-passage over 
high-density platelet beds.  BTBD4, a recently identified TF specifically expressed by 
cDCs, was found to have significantly increased expression after plate-passage.39  While 
the functional role of BTBD4 is yet undetermined, it would be interesting to explore in an 
animal model, such as the BTBD4 knockout mice, how these cDCs function in the setting 
of immune challenge, or to assess the role of BTBD4 using functional assays in both 
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ECP-induced and GMCSF/IL-4 cultured DCs.  Four TFs (VDR, NFkB2, CDKN1A and 
BCL3) demonstrated directional changes in expression with increased platelet bed 
density, suggestive of possible monocyte-platelet interactions that altered gene expression 
activation.  VDR, or vitamin D receptor, is a nuclear hormone receptor shown to play a 
role in the differentiation and function of monocyte-derived DCs.92  The ligand of VDR, 
1,25(OH)2D3 (calcitriol), is the active form of vitamin D, and is essential for the 
regulation of serum calcium and phosphate to maintain normal bone mineralization.  
Surprisingly, VDR is not just expressed in the gut or musculoskeletal system; instead it is 
expressed in essentially every tissue in the human body, thereby making vitamin D a key 
player in many conditions such as autoimmune disease, infections and cancers.93  
Vitamin D exerts its effect through the binding of nuclear VDR, which regulates 
downstream gene expression via many molecular pathways.94  Studies looking at the 
direct effect of calcitriol on monocytes and DCs have shown that it plays an essential role 
in DC differentiation and immunostimulatory capacity, through regulation of several 
genes with immune functions, particularly genes that make up a tolerogenic DC 
phenotype.95  Calcitriol treated DCs are especially adept at inducing CD4+CD25+ Tregs 
to limit the inflammatory response.96-98  It would be informative to see whether 
expression of VDR is similarly enhanced with the plate-passage of monocytes from 
CTCL and GVHD patients, and whether the upregulation of such an 
“immunosuppressive” TF is dependent on the internal milieu from which the monocytes 
are derived.  
 
Recently, the noncanonical NFkB pathway has been implicated in controlling the 
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immunoregulatory phenotypes in both classical and plasmacytoid DCs.99  The 
noncanonical NFkB pathway refers to a pathway that involves the induction of NFkB-
inducing kinase (NIK) and its downstream signaling events.  Activation of this pathway 
involves signaling through TNFR family members, such as CD40.  In a study specifically 
assessing the role of NFkB2 in DC function, NFkB2 was found to be crucial in DC 
function such as the cross-priming of CD8+ T cells.51  In a separate study looking at 
RelB, another member of the NFkB family, it was found that RelB is regulated by 
cytoplasmic NFkB2, which serves as a negative regulator of DC’s ability to express co-
stimulatory molecules and induce CD4+ T cell responses.52  Given the complexity of 
NFkB2 signaling and its myriad of downstream effects in DC maturation and function, it 
will be important to assess the functional competency of plate-passed monocyte-derived 
DCs against GMCSF/IL-4 cultured DCs and their NFkB2 expression to further explore 
the aforementioned findings. 
 
CDKN1a, a cyclin-dependent kinase inhibitor, is another TF whose expression was 
significantly elevated after plate-passage.  Kramer et al. identified the obligate role of 
CDKN1a induction in monocyte differentiation.  Monocytes induced to enter the DC 
differentiation pathway under GMCSF/IL-4 culture conditions were treated with 
CDKN1a antisense nucleotides, which blocked their phenotypic differentiation and 
ability to stimulate T cells.47  Furthermore, gene microarray data performed on DC 
exposed to T cells treated with immunostimulatory cryotreatment demonstrated 
upregulation of CDKN1a along with other genes involved in DC maturation, such as 
IL1β and Fas.100  BCL3 is a well-studied oncogene for hematopoietic malignancies such 
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as B cell chronic lymphocytic leukemias, although not much is known about its 
relationship to dendritic cell immunobiology.  Last but not least, CREM, a cAMP 
responsive element modulator, demonstrated the highest fold change in expression after 
plate-passage compared to untreated monocytes. Reports in recent literature has found 
CREM to be a possible marker of monocyte-derived DC activation.44,45,101  A comparison 
of CDKN1a, BCL3 and CREM expression on ECP-induced monocyte-derived DCs to 
GMCSF/IL-4 cultured DCs will shed further light on the impact of plate-passage on 
monocyte differentiation.  Figure 7 highlights the pertinent surface markers and 
transcription factors as they contribute to the process of monocyte-to-dendritic-cell 
differentiation.   
   
Figure 7.  Summary of the postulated roles of surface markers and transcription 
factors involved in development of monocyte-derived dendritic cells.  DC = dendritic 
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A study conducted by Woodhead et al. in 2000 demonstrated that PLAUR plays a 
functional role in DC activation of T cells using GMCSF/IL-4 cultured DCs.91  This 
highlights the importance of assessing the functional competence of ECP-induced DCs in 
the context of each of our candidate genes, many of which have available blocking 
antibodies.  To determine if plate-passed monocyte-derived DCs are capable of 
stimulating normal T cell responses to MHC Class I and II antigens or mediating 
cytotoxicity by targeting HLA on specific lymphocytes, we can employ antigen 
presenting assays or mix lymphocyte reaction assays.  Another major objective is to 
expand the number of subjects assessed to confirm the universal presence of our 
candidate genes, as well as look for gene expression in the peripheral blood of patients 
with CTCL, to assess how a diseased internal milieu or treatment with the actual ECP 
apparatus alters candidate gene expression.  We are continuing to identify additional 
surface markers from the list of 66 candidate genes using the same methodology 
described above.  Ultimately, we hope these surface markers and TFs will serve to better 
define and characterize this unique population of ECP-induced monocyte-derived DCs.  
On a more global scale, this project fits nicely into a larger endeavor to better understand 
the efficacy of the ECP apparatus, likely mediated in large part through dendritic cells, 
and have significant implications in defining a process of developing more physiologic 
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Appendix A: DNA Copy-Number Analysis of Selected Genes in Patients with CTCL 
 
I. Introduction 
Copy-number variations (CNVs) are extensive genomic structural variations that range in 
size from kilobases to megabases. CNVs can result from deletions, duplications, 
inversions and translocations, which can lead to deletion of a gene or acquisition of 
additional copies of a gene.  Early studies of genetic alterations in CTCL identified 
candidate regions containing DNA copy-number variations, some of which potentially 
correlate with disease progression and prognosis.102  Previously, a high-resolution 
genomic analysis and meta-analysis of patients with leukemic CTCL performed in our 
laboratory has defined regions of significant copy-number variation to help discern some 
of the common DNA copy-number alterations characteristic of CTCL.103  These regions 
of copy-number variation can contain a high number of genes; for example, chromosome 
17q contains over 300 genes.  This current study focuses on select regions of 
amplification to assess copy-number amplification on a gene-specific level.  
 
II. Statement of Purpose 
To validate gene specific copy number amplifications and assess whether these 
changes occur consistently across a sample population of CTCL patients, with the 
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III. Methods 
The top six regions of amplification based on the highest frequency and magnitude of 
gain from our previously published genomic analysis were selected (Table A1).103   
Within these regions of interest, 381 genes were prioritized using five selection criteria 
(Figure A1).  From this list, six genes fulfilled four of the five selection criteria and 
twenty-one genes fulfilled three of the five selection criteria.  These 27 genes were then 
further filtered for the availability of targeted therapy to comprise the final list of ten 
genes: STAT3, BECN1, SKAP1, NGFR, TAC4, PRKAR1a, HN1, GRB2, SPHK1 and 
UBR4. 
 
Table A1. Significant regions of DNA copy-number amplification described by 
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Copy number alterations occurring in these ten genes were assessed by quantitative PCR 
(TaqMan Copy Number Assays, Applied Biosystems) using DNA prepared from purified 
malignant T cells from 14 patients.  Two sets of controls were used for comparison: 
pooled DNA from CD4+ T cells of healthy volunteers and purchased pooled human 
DNA (Promega, Fitchburg, WI).  Six genes showing copy number amplification were 
further tested using DNA from 5 CTCL and 1 T-cell lymphoma cell line. 
 
IV. Results 
As Figure A2 shows, copy number amplification for each selected gene is calculated 
relative to both sets of controls (N1 = normal volunteers; N2 = Promega pooled human 
genomic DNA).  For the analysis of SKAP1, the copy number amplification calculated is 
8q23.3      17q25.1
1p36.13       3p11.1   
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closely matched between the two controls, and 8 of 14 patients were found to have copy-
number amplification >2.5 (Figure A2a).  Conversely, Figure A2b shows NGFR, which 
demonstrated poor correlation between the calculated copy-number amplifications 
between the two controls. 
 
 
Figure A2.  Representative graph of CNV in SKAP1 (a), a top-ranking candidate gene, 
showing 43% of patients with >3 gene copies.  Copy-number amplifications relative to 
both controls are comparatively similar.  In contrast, there are disparities in copy-number 
amplifications relative to controls for NGFR (b).  Genes exhibiting such differences in 
calculated CN were excluded from further analysis due to inability to ascertain true 
number of gene copies.   
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Of the ten genes, one gene was excluded from further analysis due to lack of 
amplification, three genes were excluded based on lack of correlation between the two 
controls used, and six genes were amplified in >30% of patients tested (Table A2).  Four 
genes (SKAP1, PRKAR1a, GRB2 and STAT3) were then further tested for copy-number 
amplifications using DNA from four CTCL and one T cell lymphoma cell lines.  STAT3 
was amplified in four of the six cell lines.  Amplifications of the other three genes were 
found in certain cell lines, although the results did not appear gene-specific (Table A3). 
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Table A2.  Summary of gene copy numbers calculated relative to normal (CN=2.00).  
N1 indicates pooled normal controls; N2 indicates purchased Promega normal DNA.  
Shaded boxes indicate calculated copy number amplification (CN > 2.5). 
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Figure A3.  Summary of copy number analysis for five CTCL cell lines (SeAx, Sez4, 
Pno, Hut78, MyLa) and one T cell lymphoma cell line (Jurkat). N1 indicates pooled 
normal controls; N2 indicates purchased Promega normal DNA.  Shaded boxes indicate 





In recent years, significant research effort has been directed toward understanding the 
molecular genetic events underlying multiple types of malignancies with the hopes of 
improving diagnosis and identifying novel therapeutic targets.  Studies utilizing 
comparative genomic hybridization and copy number analysis have unearthed a number 
of chromosomal abnormalities in CTCL, although with varying results.102,104-109  In this 
study, we aimed to build upon previous work performed in our laboratory to validate 
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gene-specific copy number amplifications to delineate genetic alternations characteristic 
of CTCL. 
 
Six genes within candidate regions of copy-number amplification were identified via our 
analysis: SKAP1, PRKAR1a, STAT3, BECN1, GRB2 and HN1.  SKAP1, a src kinase 
associated phosphoprotein, encodes a T-cell adaptor protein that plays a critical role in 
the T cell receptor “inside-out” signaling.  SKAP1 complexes with RapL to bind 
lymphocyte function-associated antigen 1 (LFA-1), a β2 family integrin, in a pathway 
that regulates T cell adhesion, motility and interaction time with antigen presenting 
cells.110,111  Furthermore, van Doorn et al. found that SKAP1 resides in a loci of recurrent 
gain and demonstrated copy-number amplification associated increases in expression in 
MF.112  Another candidate gene, PRKAR1a, is a cAMP-dependent protein kinase 
regulatory subunit shown to be amplified and overexpressed in analyses by Lin et. al and 
Caprini et. al.103,106  As discussed in Lin et. al, overexpression of PRKAR1a has been 
found to induce increased expression of IL-2; indeed, it is possible PRKAR1a 
amplification may result in IL-2 pathway activation, thereby enhancing the proliferation 
of malignant T cells through the up-regulation of JAK/STAT, P3K/AKT and mitogen-
activated protein kinase pathways.103,113,114  It is also noteworthy that STAT3, also 
involved in the IL-2 signaling pathway and whose constitutive activation has been 
implicated in Sézary syndrome, is another highly prioritized candidate gene.115-117  
 
Several genes were excluded from further analysis using cell line DNA due to disparities 
in copy number calculation based on the two controls employed.  This may have resulted 
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from differential binding of the chosen primers with purchased versus pooled control 
DNA.  Due to these large differences in calculated copy number, we were unable to 
accurately assess whether true amplification occurred and will defer further testing of 
these genes until further analysis.  Copy number analysis using CTCL and T cell 
lymphoma cell lines demonstrated inconsistent amplification in all genes except STAT3, 
a result consistent with previous reports of amplification and differential expression of 
STAT3 in Sézary syndrome.  Uniform amplification of all six genes was seen in Sez4 and 
Hut78 cell lines, possibly indicating more widespread genetic alterations within these cell 
lines that are reflective of potential dissimilarities between patient samples and cells 
lines, which have undergone multiple passages requiring additional growth factors.   
 
Looking forward, these genes with copy number variations will need confirmation of 
gene expression changes using quantitative real-time PCR.  If a dosage-effect is seen, 
then expression can be inhibited with siRNA technology to assess the genes’ functions in 
proliferation or cellular functions of CTCL cells.  We have long believed that persistent 
changes at the genomic level in cancer cells represent a critical target for the study of 
carcinogenesis.  We hope to have contributed to this effort through the study of selected 
candidate genes in CTCL patients as well as established cell lines, and that this may serve 
as part of the platform on which functional validation of copy number variation and 
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Recent advances in genome-wide analyses have significantly increased our understanding 
of the genomic landscape behind human diseases, including cutaneous T-cell 
lymphoma.105,106,118  The human genome is comprised of ~3 billion nucleotides of DNA; 
however, only a small percentage – 1.5 percent – of those nucleotides are actually 
translated into proteins that play a functional role in the body.  Sequencing of the 
“exome” therefore arises as an ideal strategy for the identification of genetic variants that 
underlie human disorders since the vast majority of variants that have effect on disease-
related traits encode protein.  Furthermore, the cost of whole exome sequencing remains 
significantly less expensive than whole genome sequencing, making this a novel, robust 
and cost-effective method for the identification of functional variation responsible for 
cutaneous T-cell lymphoma.119-121   
 
We hypothesized that there exist single nucleotide variants within the malignant clone of 
CTCL cells that are: 1) associated with pathogenesis, in particular those leading to the 
development of malignant or immunosuppressive phenotypes; 2) associated with 
prognosis and markers for disease staging; and 3) useful for the identification of potential 
novel targets for therapeutic intervention.  To test this hypothesis, we selected for 
phenotypically similar patients with clinically severe Sézary syndrome.  Patients enrolled 
include patients actively being treated in the photopheresis unit, past patients of 
photopheresis (currently receiving chemotherapy at Smilow Cancer Center) or past 
patients whose samples have been frozen down for previous studies conducted in our 
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department.  Malignant T lymphocytes were enriched from the peripheral blood of these 
patients using: 1) Vβ-specific antibody if available, or 2) negative selection with either 
CD7 or CD26 antibodies as determined based on phenotypic data.  Cell aliquots are 
removed during the enrichment process to assess for cell viability, to verify the purity of 
the enriched populations, as well as confirm certain phenotypic features of the cell 
populations (Figure B1).  CD4+ T cells from healthy donors are also isolated via positive 
selection using CD4+ magnetic beads for use as the control. 
 
Figure B1.  Purification of malignant T cells using negative selection.  Peripheral 
blood samples of CTCL patients are enriched for the malignant T lymphocyte population 
using negative selection with CD7 and CD26 antibodies (as determined by flow 
cytometric phenotypic data in this patient).  Cell aliquots are removed to assess for 
viability using forward and side scatter (data not shown).  Compared to the unfractionated 
population (a) with 12.4% CD3+CD4+ population, the enriched fraction is 93.5% 
CD3+CD4+ (C) as well as >99% CD7-CD26- (b).   
 
Genomic DNA was purified from 18 patients and two healthy donors.  Samples of 
sufficiently high purity were submitted for whole exome sequencing, and the 
identification of variants is currently underway with results available pending 
completion.   
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Appendix C:  Detection of peripheral blood involvement in CTCL by multi-
parametric flow cytometry analysis 
 
Identification and quantification of Sézary cells can be monitored through analysis of the 
peripheral blood, e.g. flow cytometry, including T-cell receptor variable region beta 
(TCR-Vβ).  At Yale we use multiple T cell markers for the diagnosis and tracking of 
disease burden in patients with leukemic CTCL.   We sought to explore the utility of a 
multi-parametric flow cytometry strategy in the evaluation of tumor burden in CTCL by 
conducting a prospective case-series of 13 patients referred to the Yale Photopheresis 
Clinic over 18 months.  Flow cytometry analysis was performed using multiple TCR 
markers, including: CD2, CD3, CD4, CD5, CD7, CD8, CD25, CD26, CD45, CD45RA, 
CD45RO (Yale Laboratory Medicine) and TCR-Vβ panel (ARUP Laboratories, Salt 
Lake City, UT). 
 
Flow cytometry consistently revealed a phenotypically abnormal T cell population with 
altered expression of lymphocyte markers, including CD3, CD4, CD7 and CD26.  Nine 
of the thirteen patients had loss of CD7, twelve of thirteen patients had loss CD26 and 
eight of thirteen patients had alterations in additional markers (Table C1, Figure C1).  
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Table C1.  T cell markers used at Yale to identify the neoplastic population in 
CTCL patients. Patients 1-7 have expanded TCR Vβ found on ARUP panel; patients 8-
13 do not have an identifiable TCR Vβ.  Notably, 100% of patients’ neoplastic 
populations were CD5+ and CD8- (data not shown). Loss of CD7, a common phenotype 
observed in circulating CTCL cells, was only observed in 64% of patients. 93% of 
patients had partial or complete loss of CD26.  Other significant phenotypic changes 
include alterations in CD2, CD3, CD4, CD25 and CD45. 
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Figure C1.  Initial flow cytometry analysis on Patient 1.  All plots shown are derived 
from the lymphocyte gate.  ~10% of total circulating cells (30% of lymphocytes) are 
CD3dim+ CD4dim+ CD8- CD2+ CD5+ CD7+ CD26- T cells, consistent with 
involvement of peripheral blood by the patient's known T-cell lymphoproliferative 
disease (Flow cytograms generated by Yale Laboratory Medicine). 
 
The abnormal population appeared to be highly enriched for the neoplastic T cell clone.  
In seven of thirteen patients with detectable TCR-Vβ, enrichment of TCR-Vβ in the 
abnormal population had a mean of 88% (range 66-95%) (Table C2, Figure C2). 
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Table C2.  TCR- Vβ and blood involvement characteristics of Vβ positive patients.  
Lymphocytes with atypical phenotype refer to the population delineated by markers 
shown in Table 1.  Vβ panel of antibodies (ARUP) were used to assess relative 
prevalence of T cells expressing each of these markers, specifically within the atypical 
populations.  In patients with low tumor burdens, such as patient 1, the percentage of Vβ 
in total lymphocytes is 23% vs. in 91% in the atypical population, showing that this 
population is highly enriched for the neoplastic clone. 
   
 
Figure C2.  Immunophenotypic analysis of the peripheral blood specimen from 
patient 1 performed by ARUP laboratories.  Abnormal population (CD3dim, CD4dim, 
CD8-) is 25 % of lymphocytes, and of that population, 91% express TCR Vβ 20.  This 
finding meets the criteria for T-cell monoclonality.  The other T cell subsets (bright 
CD3+, CD4+) show levels of TCR- Vβ expression close to or within normal range.  
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In patients without the presence of an obvious TCR-Vβ clone, we have nevertheless been 
able to identify the presence of a phenotypically abnormal population with alterations in 
multiple similar T cell markers (Table C1).  While the markers were variably lost from 
patient to patient, within each individual the phenotypically abnormal lymphocyte 
population retained consistent immunophenotype.  For example, the abnormal population 
in Patient 2 was consistently CD3dim, CD4dim, CD7- and CD26- over 12 months (data 
not shown).  The use of CD3, CD4, CD7 and CD26 facilitated the identification of the 
abnormal population in two patients who did not meet criteria using CD7 and CD26 
alone based on ISCL criteria.122   
 
Leukemic CTCL can mimic a number of other erythrodermic conditions clinically, 
including severe psoriasis, atopic dermatitis, GVHD and pityriasis rubra pilaris.  
Diagnosis can be facilitated by the identification of specific peripheral blood findings, 
such as an increased CD4/CD8 ratio, aberrant expression or loss of CD26 and CD7, as 
well as T cell clonality as determined by Vβ testing.123-126  However, due to only 
moderate sensitivity and specificity offered by the commonly used markers, the diagnosis 
Sézary syndrome using any single marker remains unsatisfactory.123,124,127  The addition 
of T cell receptor Vβ chain antibodies, especially when analyzed on gated T cells with an 
aberrant immunophenotype, improved detection sensitivity for the neoplastic clone as 
well as for the monitoring of tumor burden; however T cell clonality can occur under 
reactive, nonmalignant conditions and patients can have neoplastic proliferation without 
an identifiable Vβ chain.124,128-130  Therefore, the accurate diagnosis of Sézary syndrome 
likely relies upon the usage of multiple markers on flow cytometry, and our results reflect 
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added benefits of assessing for aberrant CD2, CD3, CD4, CD5 and CD45RA/RO 
expression, particularly in patients with low tumor burden.131,132 
 
Limitations of this study include the small sample size, sampling from a single academic 
center, as well as the lack of extension to clinical status and disease prognosis.  This 
project is being extended to involve larger numbers of patients with lengthier follow-up, 
and data on clinical status and treatment response will be collected towards the goal of 
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